12:27:09 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-22 Ordinarie utdelning CURAS 0.00 DKK
2024-03-21 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-03-31 Ordinarie utdelning CURAS 0.00 DKK
2023-03-30 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-03-25 Ordinarie utdelning CURAS 0.00 DKK
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-01 Extra Bolagsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-03-26 Ordinarie utdelning CURAS 0.00 DKK
2021-03-25 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriMedicinteknik
Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen är bred och har sin huvudsakliga fokus på utveckling av produkter inom området Positron Emissions Tomography (PET). Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.
2021-09-21 09:38:55

COPENHAGEN - Curasight A/S ("Curasight" or "the Company").  In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Curasight made by managerial employees and their closely associated persons. 

The Company's managerial employees and their closely associated persons have given Curasight's power of attorney on their behalf to publish trading in Curasight's warrants of series TO 1 by the Company's managerial employees and their closely associated persons. Curasight's managerial employees and their closely associated persons have exercised all their warrants of series TO 1.

The warrants of series TO 1 were issued in connection with the Company's IPO in September 2020. The transactions comprise all (100%) available warrants of series TO 1 of the following managerial employees and their closely associated persons;

Name Position Aggregated volume Price, DKK

Per Falholt Chairman of the 30,380 522,536.00
Board of directors
Lars Trolle Deputy chairman of 9,114 156,760.80
the Board of
directors
Charlotte Member of the Board 24,304 418,028,80
Vedel of directors
Andreas Kjær CSO and member of 6,076 104,507.20
the Board of
directors
Ulrich CEO and member of 6,076 104,507.20
Krasilnikoff the Board of
directors
Total 75,950 1,306,340.00

Curasight issued units (shares and consideration free warrants) in connection with the Company's IPO in September 2020, as well as the Private Placement that was executed in parallel with the IPO. Each unit consisted of eight shares and seven warrants. During the exercise period for the warrants of series TO 1, each warrant holder has the possibility, for each warrant, to subscribe for one new share in Curasight for DKK 17.20 per share. The exercise period ends on 7 October 2021.

The proceeds that the Company will receive through the warrant exercise will finance Curasight's clinical development plan.